GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » abrdn Life Sciences Investors (NYSE:HQL) » Definitions » Price-to-Operating-Cash-Flow

HQL (abrdn Life Sciences Investors) Price-to-Operating-Cash-Flow : 42.67 (As of Jul. 08, 2025)


View and export this data going back to . Start your Free Trial

What is abrdn Life Sciences Investors Price-to-Operating-Cash-Flow?

As of today (2025-07-08), abrdn Life Sciences Investors's share price is $12.93. abrdn Life Sciences Investors's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.30. Hence, abrdn Life Sciences Investors's Price-to-Operating-Cash-Flow Ratio for today is 42.67.

The historical rank and industry rank for abrdn Life Sciences Investors's Price-to-Operating-Cash-Flow or its related term are showing as below:

HQL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 0   Med: 0   Max: 43.2
Current: 42.66

During the past 8 years, abrdn Life Sciences Investors's highest Price-to-Operating-Cash-Flow Ratio was 43.20. The lowest was 0.00. And the median was 0.00.

HQL's Price-to-Operating-Cash-Flow is ranked worse than
82.41% of 995 companies
in the Asset Management industry
Industry Median: 13.65 vs HQL: 42.66

abrdn Life Sciences Investors's Cash Flow from Operations per share for the six months ended in Mar. 2025 was $0.30. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.30.


abrdn Life Sciences Investors Price-to-Operating-Cash-Flow Historical Data

The historical data trend for abrdn Life Sciences Investors's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

abrdn Life Sciences Investors Price-to-Operating-Cash-Flow Chart

abrdn Life Sciences Investors Annual Data
Trend Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial - - - - -

abrdn Life Sciences Investors Semi-Annual Data
Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of abrdn Life Sciences Investors's Price-to-Operating-Cash-Flow

For the Asset Management subindustry, abrdn Life Sciences Investors's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


abrdn Life Sciences Investors's Price-to-Operating-Cash-Flow Distribution in the Asset Management Industry

For the Asset Management industry and Financial Services sector, abrdn Life Sciences Investors's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where abrdn Life Sciences Investors's Price-to-Operating-Cash-Flow falls into.


;
;

abrdn Life Sciences Investors Price-to-Operating-Cash-Flow Calculation

abrdn Life Sciences Investors's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=12.93/0.303
=42.67

abrdn Life Sciences Investors's Share Price of today is $12.93.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. abrdn Life Sciences Investors's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.30.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

abrdn Life Sciences Investors Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of abrdn Life Sciences Investors's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


abrdn Life Sciences Investors Business Description

Traded in Other Exchanges
N/A
Address
1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.
Executives
Bill Maher director 600 WEST BROADWAY, 30TH FL., SAN DIEGO CA 92101
Rose Dimartino director C/O ABRDN, 1900 MARKET STREET, PHILADELPHIA PA 19103
Kathleen Goetz director 1310 OAK VALLEY CIRCLE, POLK CITY IA 50226
Todd Reit director C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
James Joseph O'connor other: Director of Adviser C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Marika Tooze other: Director of Adviser C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Aberdeen Standard Investments Inc. other: Adviser 1900 MARKET ST., 2ND FLOOR, PHILADELPHIA PA 19103
Jaclyn Marie Matsick other: Director of Adviser C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Lucia Sitar officer: VP and Chief Legal Officer 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Jennifer A Nichols other: Director of Adviser 1735 MARKET STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Christian Pittard officer: President ONE BOW CHURCHYARD, LONDON X0 EC4M 9HH
Megan Kennedy officer: Secretary and Vice President 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Sharon Ferrari officer: Treasurer and CFO 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Alan R Goodson officer: Vice President 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Joseph Andolina officer: Chief Compliance Officer & VP 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103

abrdn Life Sciences Investors Headlines

From GuruFocus

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 11-15-2022

HQL Declares $0.43 Monthly Dividend Yielding 41.92%

By GuruFocus News 05-12-2025

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 11-12-2021

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 06-30-2022

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 03-31-2023

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 05-17-2022

Tekla Life Sciences Investors Paid Distribution

By Business Wire 06-30-2023